Evaluation of Competencies in Scientific Writing and Attendees' Satisfaction After Two Different Types of Training Courses: SCRIU-B Study (SCRIU-B)

March 22, 2023 updated by: Dr. Antoni Esteve Foundation

Evaluation of the Acquisition of Competencies and Participants' Satisfaction After a Scientific Writing Course: Comparison of Face-to-face and Online Modalities Through a Non-randomized Open Clinical Trial (SCRIU-B Study)

Scientific writing is one of the competencies required and requested by health professionals. There are several course formats designed for acquiring these competencies, although the improvement after taking part in these courses is not always demonstrated. Through an open and non-randomized experimental design, the SCRIU-B study aims to evaluate the acquisition of competencies in scientific writing after specific training courses (face-to-face and online) as well as the satisfaction of the participants with these courses. A control group with participants from other training workshops not related to scientific writing is included. Through different questionnaires about knowledge, attitudes, and skills we will evaluate and compare the improvement of their scientific writing skills. The results of the study will allow us to assess the usefulness of these courses and improve their format and implementation.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Enrolling by invitation

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Scientific writing and scientific publications are fundamental to the advancement of science in general. However many science degrees do not have specific writing courses. Several initiatives have attempted to improve scientific writing skills through face-to-face or online courses. However, few studies have analyzed the short- and long-term outcomes of these training interventions. Our objective is to evaluate the short- and long-term skills in scientific writing and the level of satisfaction of a group of students after taking a scientific writing course, in two training modalities (face-to-face and online).

The study will assess the scientific writing skills of those attending the course "Cómo redactar un artículo científico" in face-to-face and online format during 2019 and 2022 through a non-randomized open trial type study with a comparison group. The study will use questionnaires to analyze the participants' satisfaction with the course, their knowledge about scientific writing, and their attitude and skills toward scientific writing (knowledge, attitudes, and skills). The satisfaction questionnaire will be provided immediately after the course. The scientific writing skills of the attendees will be compared with a control group. The study is estimated to analyze the results of 270 participants, 90 per group. This protocol has been reviewed and approved by an ethics committee.

The study will be carried out between 2019 and 2022 and participants will be recruited from 6 face-to-face and 4 online editions of the scientific writing course. We aim to analyze the real impact these seminars have on the scientific writing skills of their participants and demonstrate that face-to-face courses are more useful than online courses.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Anticipated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
270

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Spain
      • Barcelona, Spain, 08038
        • Dr. Antoni Esteve Foundation

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants of the Esteve Foundation training workshops

Exclusion Criteria:

  • Students who do not accept to participate in the study at the time of enrolment for the training course.
  • Students who attended/enrolled in a Esteve Foundation's scientific writing course (face-to-face or online) prior to the study.
  • Students who enroll in another Esteve Foundation's scientific writing course during the duration of the study.
  • Students who have enrolled in other courses on scientific writing 12 months prior to recruitment for this study or during the duration of this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Non-Randomized
  • Interventional Model: Factorial Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: GIP - Face-to-face intervention group
Participants in the scientific writing face-to-face training course.
Other: Scientific writing training course
Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
Active Comparator: GIO: Online intervention group
Participants in the scientific writing online training course.
Other: Scientific writing training course
Attendance to a training course on scientific writing. Attendees learn about the importance of scientific writing, structure and writing an original paper, how scientific publishing works, as well as how to interact with journal editors and reviewers.
No Intervention: GIC: Control intervention group
Participants in other face-to-face training courses not related to scientific writing.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Participants' satisfaction about the training course
Time Frame: 2 to 62 days
Participants' satisfaction will be collected through a 14-item opinion questionnaire about the course with a Likert scale from 0 (minimum) to 10 (maximum). These 14 items include: overall opinion of the course, usefulness of the materials, usefulness of the in-class exercises, teaching capacity of the lecturers, duration of the course, usefulness of the new knowledge acquired in their current job, etc. Data will be analyzed using descriptive statistics. Items and overall scores will be compared between each of the 3 groups/arms of the study.
2 to 62 days
Participants' knowledge about scientific writing
Time Frame: 20 months
Participants' general knowledge about scientific writing will be analyzed through a multiple-choice 8-item test that each participant will have to answer three times throughout the study (before, after and 18 months after the intervention). The knowledge test includes specific questions about scientific style, authorship requirements, editorial policies and characteristics of an original scientific article, among others. Correct answers will score 1 point and incorrect answers will score 0 (zero) points. Increase or decrease in knowledge will be determined by the differences through time in the overall scores of the three groups/arms of the study, differences on overall scores by participant (whole test) and differences by item and participant (score differences of the same item through time of the same participant). Data will be analyzed using descriptive statistics. Items and overall scores will be compared between each of the 3 groups/arms of the study.
20 months
Participants' attitudes towards scientific writing
Time Frame: 20 months
Participants' opinion about their own capability towards scientific writing will be analyzed through a 5-item capability questionnaire with a Likert scale from 0 (minimum, not capable at all) to 10 (maximum, completely capable). The participants will state their opinion on their personal capability to write different types of scientific texts related to the publication of a scientific article such as scientific manuscripts for national and international audiences, abstracts, the presentation letter and the answers to the reviewers. Increase or decrease in capability will be determined by differences through time in the overall scores for each participant (whole test), overall score by group/arm and differences by item and participant through time. Data will be analyzed using descriptive statistics. Items and overall scores will be compared between each of the 3 groups/arms of the study.
20 months
Students' skills in scientific writing
Time Frame: 20 months
Participants' skills in scientific writing will be analyzed by comparing the number and types of scientific publications and their authorship role in them before and 18 months after the intervention.
20 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Dr. Antoni Esteve Foundation

Collaborators

Collaborators

An organization other than the sponsor that provides support for a clinical study. This support may include activities related to funding, design, implementation, data analysis, or reporting.
Institut Català d'Oncologia
Institut d'Investigació Biomèdica de Bellvitge
University of Valencia
University of Barcelona
University of Alicante
Ciber de Enfermedades Respiratorias
CIBER de Epidemiología y Salud Pública

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Study Director: Felix Bosch, MD PhD, Director

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
July 5, 2019

Primary Completion (Anticipated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 31, 2023

Study Completion (Anticipated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 31, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
September 21, 2022

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 22, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
April 4, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
April 4, 2023

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
March 22, 2023

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
March 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FDAE20220714

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Scientific Writing Training Course

Clinical Trials on Scientific writing training course

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings